Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, CT Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021

Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, CT Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021

Short bowel syndrome (SBS) is a group of problems related to poor absorption of nutrients. Short bowel syndrome typically occurs in people who have had at least half of their small intestine removed and sometimes all or part of their large intestine removed, significant damage of the small intestine, poor motility, or movement, inside the intestines. diagnoses short bowel syndrome based on a medical and family history, a physical exam, blood tests, fecal fat tests, an x-ray of the small and large intestines, upper gastrointestinal (GI) series, computerized tomography (CT) scan, etc. Treatment will often include medications, and in some instances surgery. General medications to treat short bowel syndrome include antibiotics to prevent bacterial overgrowth, H2 blockers to treat too much gastric acid secretion, proton pump inhibitors to treat too much gastric acid secretion, choleretic agents to improve bile flow and prevent liver disease, bile-salt binders to decrease diarrhea, anti-secretin agents to reduce gastric acid in the intestine, hypomotility agents to increase the time it takes food to travel through the intestines, leading to increased nutrient absorption, growth hormones to improve intestinal absorption, teduglutide to improve intestinal absorption. Typically, the SBS treatment regime includes Teduglutide (Gattex) hormone, L-glutamine, or Somatropin (Zorbtive), a human growth hormone.

The global short bowel syndrome diagnostics and treatment market segmentation is based on test type (complete blood test, fecal fat test, imaging tests such as X-ray, CT scan, others) and drug class (GLP-2, growth hormones, and L-glutamine, others).

The global short bowel syndrome diagnostics and treatment market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global short bowel syndrome diagnostics and treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global short bowel syndrome diagnostics and treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global short bowel syndrome diagnostics and treatment market and included in this report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio and Company, Inc., Shire plc, and Zealand Pharma A/S.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Short Bowel Syndrome Diagnostics and Treatment Market

1. Test Type
1.1. Complete Blood Test
1.2. Fecal Fat Test
1.3. Imaging Tests
1.3.1. X-ray
1.3.2. CT Scan
1.4. Others

2. Drug Class
2.1. GLP-2
2.2. Growth Hormones
2.3. L-Glutamine
2.4. Others

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Ardelyx, Inc.
4.2. Emmaus Life Sciences, Inc.
4.3. GLyPharma Therapeutic, Inc.
4.4. Merck KGaA
4.5. Naia Pharmaceuticals, Inc.
4.6. Nutrinia Ltd.
4.7. OxThera
4.8. Sancilio and Company, Inc.
4.9. Shire plc
4.10. Zealand Pharma A/S

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*